Epilepsy Neurobionic Device - Animation Animation of Epilepsy Treatment Device being developed by the Bionics Institute, University of Melbourne and St Vincents Hospital.From:BionicsInstituteViews:104 2ratingsTime:00:16More inScience Technology The rest is here: Epilepsy Neurobionic Device - Animation - Video … Continue reading →

Epilepsy experts talk about the future of epilepsy treatment Interviews from Professors Michele Simonato and Helen Cross from the 10th European Congress on Epileptology, London 2012From:epilepsyactionViews:212 1ratingsTime:02:44More inNonprofits Activism Continued here: Epilepsy experts talk about the future of epilepsy treatment - Video … Continue reading →

Comprehensive Epilepsy Program Overview- Brien Smith, MD, and Kost Elisevich, MD, PhD Dr. Smith and Dr. Elisevich describe the care available at West Michigan's first Level 4 epilepsy center which provides the highest level of comprehensive medical and surgical evaluation and treatment for both children and adults with epilepsy and seizure disorders.From:spectrumhealthtvViews:68 0ratingsTime:05:08More inPeople Blogs Originally posted here: Comprehensive Epilepsy Program Overview- Brien Smith, MD, and Kost Elisevich, MD, PhD - Video … Continue reading →

Medications for Epilepsy: Linda Selwa, MD, University of Michigan Health System While the goal of epilepsy treatment is "No seizures, no side effects," reaching that goal can sometimes be a challenge. This call discusses current and future medications for epilepsy, common side effects, potential long-term effects to consider, effectiveness of different drugs for different types of seizures, generics vs. brand name medications, financial considerations, and more.From:EpilepsyMichiganViews:7 0ratingsTime:01:14:48More inNonprofits Activism Original post: Medications for Epilepsy: Linda Selwa, MD, University of Michigan Health System - Video … Continue reading →

John's epilepsy story John speaks on his epilepsy treatment at UCLAFrom:lindyrattiesViews:13 0ratingsTime:07:41More inEntertainment Read the rest here: John's epilepsy story - Video … Continue reading →

(Reuters) - U.S. health regulators approved Japanese drugmaker Eisai Co Ltd's Fycompa tablets to treat partial seizures in epileptic patients, saying current treatments on the market were unsatisfactory in controlling seizures in some patients. Eisai's drug, chemically known as perampanel, works by blocking the action of the neurotransmitter glutamate, which may cause excessive electrical activity in the brain, resulting in seizures. "It is important to have a variety of treatment options available for patients with epilepsy," said Russell Katz, an official at the U.S. Food and Drug Administration's Center for Drug Evaluation and Research. The drug was approved specifically for epileptic patients aged 12 and above, based on Fycompa outperforming a placebo in three clinical studies, the FDA said. Dizziness, weight increase, blurred vision and excessive sleep were among some of the most common adverse events reported by patients taking Fycompa. The drug will carry a boxed warning alerting prescribers and patients about the risks of aggression, anger, anxiety, paranoia and agitation among other mental status changes, the health regulator said. The drug will be sold along with a patient medication guide containing instructions on its use and drug safety information. (Reporting by Zeba Siddiqui in Bangalore; Editing by Roshni … Continue reading →

By Dan Radovsky | More Articles October 23, 2012 | The U.S. Food and Drug Administration announced Monday that it has approved a new drug, Fycompa, for the treatment of partial onset seizures in adult epilepsy patients. The FDA approval came after three clinical trials showed Fycompa's effectiveness in controlling partial seizures, the most common type of seizures in epilepsy patients. "Some people with epilepsy do not achieve satisfactory seizure control from treatments they are currently using, said Russell Katz, M.D., of the FDA's Center for Drug Evaluation and Research. "It is important to have a variety of treatment options available for patients with epilepsy." The drug had previously been approved for use by the European Commission. More than 50 million people live with epilepsy around the world. Fycompa is produced by Japanese company Eisai, which has its U.S. operations based in Woodcliff Lake, N.J. View original post here: FDA Approves New Epilepsy Drug … Continue reading →

WebMD Health News Oct. 24, 2012 -- Fycompa (perampanel) has received FDA approval for the treatment of partial onset seizures among epilepsy patients aged 12 and older. The new drug is the first of a new class of epilepsy medications and joins the ranks of other medications available to the estimated 2 million Americans with epilepsy.More than one-third of people with epilepsy experience seizures despite taking currently available treatments, according to the CDC. Some people with epilepsy do not achieve satisfactory seizure control from treatments they are currently using, says Russell Katz, MD, director of the Division of Neurology Products in the FDAs Center for Drug Evaluation and Research. It is important to have a variety of treatment options available for patients with epilepsy. Epilepsy is the fourth most common neurological disorder following migraine, stroke, and Alzheimers disease, according to the Epilepsy Foundation. The chronic condition causes seizures brought on by abnormal electrical activity in the brain. Seizures can affect movement, the senses, emotions, and behavior. Partial seizures, the type that Fycompa is designed to treat, are the most common type of seizure. About 60% of epilepsy patients have partial seizures, which involve only one part of the brain.They can, … Continue reading →

BRUSSELS (Reuters) - Belgian pharmaceuticals group UCB said on Monday that sales of its three new main products had for the first time overtaken those of its expiring blockbuster epilepsy treatment Keppra and retained its full-year guidance. UCB, which makes drugs targeted at diseases of the immune and central nervous systems, said on Monday sales of Cimzia, Neupro and Vimpat rose 50 percent to 665 million euros over the first nine months and were now treating about 382,000 patients. UCB said it was on course to reach its goal of 1.5 million patients treated with the three drugs, with combined peak sales of at least 3.1 billion euros, in the second half of the decade. Sales of Cimzia, treating bowel disorder Crohn's disease and rheumatoid arthritis, rose 51 percent to 334 million euros. For Neupro, a patch used for Parkinson's disease and restless leg syndrome, sales were up 33 percent to 93 million euros. Sales of Vimpat, UCB's next generation epilepsy drug, increased 54 percent to 237 million euros. Keppra sales dropped 13 percent to 652 million euros as generic competitors took advantage of its patent expiry in Europe and North America. In the first half, sales of Keppra were … Continue reading →

Prize Winner to Be Announced at the Antiepileptic Drug and Device Trials XII Conference WASHINGTON, Oct. 25, 2012 /PRNewswire-USNewswire/ --The Epilepsy Therapy Project (ETP), a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and the parent organization of epilepsy.com, today announced its second annual "Shark Tank" Competition. ETP is inviting entries that represent the most innovative new ideas in epilepsy treatment and care. The deadline for submission is January 15, 2013 at 6 p.m. Eastern.The winner of the 2013 Shark Tank Competition will receive national recognition and a $100,000 cash award to support the development and commercialization of an important new product, technology or therapeutic concept. The top finalists will present their product concepts or therapeutic candidates at the Antiepileptic Drug and Device Trials (AEDD) XII Conference in Miami being held on May 15-17, 2013. The winning entry will be selected by live voting at the conference by an expert panel of judges and audience members representing industry, patient advocacy, investment, research and medical communities.The project deemed most innovative will be announced at the conclusion of the conference, and the winner will receive a $100,000 grant to help accelerate the idea from … Continue reading →